Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1522282 (
EMT
)
2,868
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
BACKGROUND Osteosarcoma is a major bone malignancy in children and young adults, and it is highly heterogeneous. The clinical outcome of osteosarcoma is individual-dependent due to different genetic and pathological profiles. Although chemotherapy in combination with surgery has significantly improved the survival of localized disease, the prognostic improvement for metastatic patients is less marked.
ECT2
(epithelial cell transforming sequence 2) is a transforming protein that can interact with Rho-like proteins of the Ras family and has been proven as an ontogenetic protein in cancer cell lines. We studied the clinical significance of
ECT2
in osteosarcoma and explored its underlying oncogenic mechanisms. MATERIAL AND METHODS The protein expression pattern of
ECT2
in osteosarcoma was investigated by immunohistochemical staining, and its association with clinicopathological characteristics was initially explored. The significance of
ECT2
in predicting patient prognosis was verified by univariate and multivariate analyzes. Cellular experiments were conducted to explore underlying mechanisms of
ECT2
in regulating osteosarcoma progression. RESULTS High
ECT2
expression was correlated with tumor metastasis and poor overall survival of osteosarcoma patients.
ECT2
promotes cell invasion by modulating
EMT
process. CONCLUSIONS
ECT2
is an independent prognostic factor for osteosarcoma and it can upregulate the metastatic capacity of osteosarcoma cells.
...
PMID:Role of Epithelial Cell Transforming Sequence 2 (ECT2) in Predicting Prognosis of Osteosarcoma. 2879 4
